Defining small vessels and bioresorbable vascular scaffold outcomes

Poonam Velagapudi MD,

Poonam Velagapudi MD

Division of Cardiology, Rhode Island Hospital, Brown Medical School, Providence, Rhode Island

Search for more papers by this author

J. Dawn Abbott MD, FSCAI,

Corresponding Author

J. Dawn Abbott MD, FSCAI

[email protected]

Division of Cardiology, Rhode Island Hospital, Brown Medical School, Providence, Rhode Island

Correspondence to: J. Dawn Abbott, MD, Division of Cardiology, Rhode Island Hospital, Associate Professor Brown Medical School, 814 APC, 593 Eddy St, Providence, RI. E-mail: [email protected]Search for more papers by this author

Poonam Velagapudi MD,

Poonam Velagapudi MD

Division of Cardiology, Rhode Island Hospital, Brown Medical School, Providence, Rhode Island

Search for more papers by this author

J. Dawn Abbott MD, FSCAI,

Corresponding Author

J. Dawn Abbott MD, FSCAI

[email protected]

Division of Cardiology, Rhode Island Hospital, Brown Medical School, Providence, Rhode Island

First published: 13 September 2016

https://doi.org/10.1002/ccd.26707

Conflict of interest: Nothing to report.

Share a link

Email
Wechat
Bluesky

Key Points

Bioresorbable vascular scaffolds (BVS) are non-inferior to second generation drug eluting stents (DES) but thrombosis rates for BVS in small vesseles is a concern.
The BVS-SAVE registry of small vesseles (<2.75 mm) supports safety and efficacy of BVS in this high risk lesion subset.
Definitive recommendation for BVS in small vessels require further trials DES with evaluation of the lower threshold for minimal reference vesseles diameter.

REFERENCES

1 Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 2015; 373: 1905–1915.
10.1056/NEJMoa1509038
CAS PubMed Web of Science® Google Scholar
2 Stone G, Ellis E, Simonton C, Metzger D, Caputo R, Rizik D, Teirstein P, Popma J, McMeans J, Zhang Z, Kereiakes D. Outcomes of the absorb bioresorbable vascular scaffold in very small and very small coronary arteries. THE ABSORB III RANDOMIZED TRIAL. J Am Coll Cardiol 2016; 67: 35–35. doi:10.1016/S0735-1097(16)30036-5.
10.1016/S0735-1097(16)30036-5
Web of Science® Google Scholar
3 Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn RJ, Smits P, Koolen J, Meredith I, Li X, Miquel-Hebert K, Veldhof S, Garcia- Garcia HM, Ormiston JA, Serruys PW. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: Does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013; 99: 98–105.
10.1136/heartjnl-2012-302598
CAS PubMed Web of Science® Google Scholar
4 Latini R, Granat F, Ielasi A, Varricchio A, Moscarella E, Tespili M, Cortese B. Bioresorbable vascular scaffolds for SmAll vessels coronary disease: The BVS-SAVE registry. Catheter Cardiovasc Interv 2016; 88: 380–387.
10.1002/ccd.26516
PubMed Web of Science® Google Scholar

Volume88, Issue3

September 2016

Pages 388-389

SCAI Member Sign in

Defining small vessels and bioresorbable vascular scaffold outcomes

Key Points

REFERENCES

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Defining small vessels and bioresorbable vascular scaffold outcomes

Key Points

REFERENCES

References

Related

Information